Empagliflozin's Novel Cardioprotective Mechanism in Non-Diabetic Myocardial Infarction with Acute Hyperglycemyocardial Infarction

Arundhati Guru^*
*Correspondence: Arundhati Guru, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Piazza Umberto I, 1, 70121 Bari BA, Italy, Email:

Keywords

Cardioprotective mechanism • Myocardial infarction • Hyperglycemyocardial infarction

Description

Individuals who experienced both acute myocardial infarction and hyperglycemic myocardial infarction upon admission to the hospital had a worse prognosis than those who did not. The ability of sodium-glucose co-transporter-2 myocardial infarction inhibitors to treat acute hyperglycemic myocardial infarction and the underlying processes remains unknown. When non-diabetic myocardial infarction caused by a glucose injection co-occurred with acute hyperglycemic myocardial infarction in WT myocardial infarction. The survival rate was lower than in the control group. After using empagliflozin, a notable improvement in LV function and survival was seen. Also, when a myocardial infarction was coupled with an acute hyperglycemic myocardial infarction, empagliflozin decreased fibrosis and autophagy of border cardiac tissue [1].

Using myocardial infarction models with Beclin1+/- and NHE1 cKO, we discovered that Beclin1 deficiency increased survival. Inhibiting autophagy by focusing on Beclin1 rather than NHE1 allowed EMPA to have a more significant cardioprotective impact. Moreover, empagliflozin prevented autophagic cell death in cardiomyocytes caused by Tat-beclin1 or GD by rescuing them from autosis. These results offer novel insights into the mechanism by which sodiumglucose co-transporter-2 inhibitor effectively reduces myocardial injury in nondiabetic myocardial infarction with acute hyperglycemic myocardial infarction by suppressing beclin1-dependent autosis rather than by elusively targeting NHE1 in cardiomyocytes [2].

Although though acute myocardial infarction treatment has advanced recently, the condition still has a high mortality rate and certain serious consequences that can be fatal. Regardless of the presence of confirmed diabetes mellitus, acute hyperglycemic myocardial infarction is a frequent occurrence in the initial stages of acute myocardial infarction. Significant acute hyperglycemic myocardial infarction occurs in at least 10% of non-diabetic patients with acute myocardial infarction. Several research conducted over the past ten years have discovered a link between acute hyperglycemic myocardial infarction and poor outcomes in patients with acute myocardial infarctionIt is a standalone predictor of myocardial infarction-related short- and long-term mortality. Moreover, one of the most frequent side effects that can raise the risk of death in people with acute myocardial infarction, particularly acute hyperglycemic myocardial infarction, is heart failure. In order to treat and prevent post-myocardial infarction with acute hyperglycemic myocardial infarction and heart failure, new targets must be researched [3].

When under stress, autophagy, a crucial process that helps to destroy damaged organelles and cytoplasm, plays a protective role for the cell. By eliminating damaged organelles, increased basal autophagy may increase lifespan. Autophagy, which is characterised by the production of autophagosomes and cytoplasmic vacuolization after myocardial infarction, may also play a significant role in the regulation of cell death. Many cardiac conditions, including heart failure, cardiac hypertrophy, myocardial infarction and diabetic cardiomyopathy, are linked to autophagy dysfunction. Excessive cardiomyocyte autophagy manifests as a result of myocardial infarction and ischemic heart disease which causes cardiomyocyte death and dysfunction. In heart failure caused by post-myocardial infarction with acute hyperglycemic myocardial infarction, autophagy may therefore be a significant therapeutic target [4].

The transmembrane protein sodium-glucose co-transporter-2, which is mostly found in renal proximal tubular cells, is in charge of reabsorbing glucose. Sodium-glucose co-transporter-2 inhibitors reduce cardiovascular mortality in the type 2 diabetes model and excrete extra glucose in the urine, which reduces the severity of diabetic sequelae. Inhibitors of sodium-glucose co-transporter-2 lessen the oxidative stress and fibrosis in the diabetic myocardium and hasten the healing of atherosclerosis. The preventive effects of sodium-glucose co-trans myocardial infarction porter-2 inhibitors in heart failure were also noted by clinical researchers [5].

For instance, the EMPACT-myocardial infarction study informs clinical practise about the use of empagliflozin in patients with a high risk of developing heart failure later in life and dying from their myocardial infarction. However, it is still unclear if sodium-glucose co-transporter-2 inhibitors' ability to prevent heart failure is caused by a mechanism other than the diuretic one. Hence, we investigated how sodium-glucose co-transporter-2 inhibitors affect the function of cardiomyocytes and the heart in both vivo and in vitro.

Our earlier research shown that the sodium-glucose cotransporter-2 inhibitor EMPA can decrease autophagy flux by concentrating on the Na+/H+ transporter NHE1 on cardiomyocytes, preventing the death of cardiomyocytes as a result of excessive autophagy and acting as a cardioprotective agent. The extract of Panax notoginseng, used in traditional Chinese medicine, has been shown to have some cardioprotective properties in cases of myocardial infarction. The method by which this occurs is by inducing autophagy in cardiomyocytes. We examined the effects of EMPA or EMPA plus Panax notoginseng saponins on myocardial infarction accompanied by acute hyperglycemic myocardial infarction and found that EMPA improved cardiac function and survival, in light of the critical role that autophagy plays in cardiomyocytes of myocardial infarctionThe current study sought to determine whether sodium-glucose co-transporter-2 inhibitors can also improve nondiabetic myocardial infarction with acute hyperglycemic myocardial infarction a and identify the underlying cardioprotective mechanisms based on Beclin1+/- and NHE1 cKO myocardial infarction of myocardial infarction accompanied by acute hyperglycemic myocardial infarction [6].

Wild-type (WT) C57BL/6 J male myocardial infarction was used. The CRISPR/Cas9 system produced myocardial infarctions that were Nhe1-/- and Beclin1+/-. All myocardial infarction patients were housed in cages with free access to food and water in a temperature-controlled setting with a 12-hour light/ dark cycle.

Myocardial infarction were infused with glucose at a rate of 2 g per kg of body weight 15-20 myocardial infarction before surgery for the acute hyperglycemic myocardial infarction model. The tail tip of the tail was selected as the time point of 0 myocardial infarction and blood glucose was monitored from there. At time 0-120 after myocardial infarction, glucose levels were assessed as previously mentioned. The other control groups received DMSO, whereas the EMPA treatment groups were given EMPA (30 mg/kg) by gavage once daily for one week. Myocardial infarction were administered with 100 mg/kg PNS once daily for a week as part of the PNS administration. Myocardial infarction patients were put on the operating table after receiving respiratory anaesthetic with 1-2% isoflurane. The heart was made visible by opening the myocardial infarction patient's left chest, which had previously been depilated and cleaned. Using 6-0 polyester suture, the left anterior descending branch was tied off 1 mm below the left atrial appendage. Afterwards, layer by layer, the skin and ribs from the myocardial infarction were stitched. To record ST-segment elevation during cardiac occlusion, the ECG was watched. One or two weeks after the myocardial infarction, the animals were put to sleep and samples were taken for analysis.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ishihara, Masaharu. "Acute hyperglycemia in patients with acute myocardial infarction."CircJCIRC J 76 (2012): 563-571.

Google Scholar, Crossref, Indexed at

2. Zarich, Stuart W and Richard W Nesto. "Implications and treatment of acute hyperglycemia in the setting of acute myocardial infarction."Circulation115 (2007): e436-e439.

Google Scholar, Crossref, Indexed at

3. Marfella, Raffaele, Mario Siniscalchi, Katherine Esposito and Ausilia Sellitto, et al. "Effects of stress hyperglycemia on acute myocardial infarction: Role of inflammatory immune process in functional cardiac outcome."Diabetes care26 (2003): 3129-3135.

Google Scholar, Crossref, Indexed at

4. Bellodi, Giorgio, Valeria Manicardi, Vincenzo Malavasi and Leonarda Veneri, et al. "Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus." AmJCard 64 (2039): 885-888.

Google Scholar, Crossref, Indexed at

5. Van der Horst, Iwan CC, Maarten WN Nijsten, Mathijs Vogelzang and Felix Zijlstra. "Persistent hyperglycemia is an independent predictor of outcome in acute myocardial infarction." Cardiovasc Diabetol 6 (2007): 1-8.

Google Scholar, Crossref, Indexed at

6. Koracevic, Goran P. "Proposal of a new approach to study and categorize stress hyperglycemia in acute myocardial infarction."J Emerg Med 51 (2016): 31-36.

Google Scholar, Crossref, Indexed at